Nav: Home

Scientists show cognitive-enhancing drugs can improve chess play

March 06, 2017

The first study to both show and measure the effects of cognitive-enhancing drugs such as modafinil, methylphenidate (best known under the trade name Ritalin), and caffeine, on chess play is being published in the March edition of the peer-reviewed journal European Neuropsychopharmacology*. This shows significant cognitive improvements for modafinil and methylphenidate, and may have influence how these drugs are used off-label in a range of activities.

The study shows how certain drugs can alter and even improve the way in which the brain processes complex information. As applied to chess (and other fields), this supports the possibility pharmaceutical enhancement giving a player a competitive advantage. The World Chess Federation, FIDE, recognised this by introducing an anti-doping code in 2014 (note1).

Now a new double-blind randomised controlled trial by scientists from German and Swedish universities has shown that the cognitive enhancing drugs, modafinil, methylphenidate, and caffeine can improve chess play. Previous research had shown that the drugs could improve cognitive performance when a subject was tired or was performing below his or her optimal performance, but this is the first work to show improvement of cognitive performance even if the subject is performing at a very high level.

The team, led by Professor Klaus Lieb (University of Mainz, Germany) gave 39 male chess players controlled doses of one of the drugs modafinil, methylphenidate, caffeine, or a placebo. They then played a series of rapid, time-limited (15 minutes) games against a chess programme (the popular Fritz 12 programme) which had been matched to the strength of each individual player. This was a 4-day "crossover" study, meaning that the player had who taken modafinil on day 1 would receive a different drug (or placebo) on each subsequent day, and so on. In total the researchers gathered data from over 3000 chess games.

"One of the strengths of this study is that the chess programme provides a reference point to measure the cognitive effect", commented Professor Lieb, "

They found that all three substances tested caused the players to increase the time needed to decide on a move, meaning that more games were lost as the players ran out of time. However, when the analysis was corrected to take out games lost on time, the team found that both modafinil and methylphenidate significantly increased the players' scores, whereas caffeine showed a more modest, but not statistically significant improvement.

"We were surprised to see that players on the drugs played more slowly than normal, indicating that their thought processes seemed to be deeper" said Professor Lieb.

He continued:

"The key to this work is in understanding that players showed an improvement if under less time pressure. The results themselves would be pretty significant in chess terms. For example, both modafinil and methylphenidate gave an improvement coefficient of around 0.05. If we correct for the slowest players, then the effect would be the equivalent of moving a player from say, number 5000 in the world ranking, to number 3500 in the world ranking. In a single game, the effect is the equivalent of having the white pieces, every time, which give around a 5% better chance of winning.

These differences can be pretty significant in a competitive sport or game. But this work also allows us to put a figure on the way that the use of these drugs can affect the way we think in a range of everyday intellectual activities, such as studying for an exam."

The researchers stress that the use of these drugs as cognitive enhancers are 'off-label' uses, and may have significant side effects, especially with repeated use. As all pharmaceutical substances have risks and benefit, there is little data that compares the benefit of cognitive enhancement against any risk or side effect. They also note that this is a comparatively small study, and requires replication before firm conclusions can be drawn.

Trevor Robbins (Professor of Cognitive Neuroscience at the University of Cambridge), who was once ranked in the top 20 chess players in England, commented:

"Chess involves several higher brain processes including working memory, planning, cognitive flexibility and cognitive control. Drugs such as modafinil have previously been found to enhance performance of such cognitive functions in laboratory based studies of non-sleep deprived volunteers, although sometimes at the cost of prolonging response times.

This work, one of the first to study drug effects on chess, shows that these performance enhancements can translate into real-world activities in this study of chess players who improved their performance, though sometimes at the cost of losing on time. ".

Professor Robbins won the Brain Prize in 2014, which is considered the most important international neuroscience prize.

Professor David Nutt (Imperial College), ex-President of the European College of Neuropsychopharmacology, added:

"We have known for decades that stimulants improve sustained performance through reducing fatigue effects on attention and vigilance. So these current data provide new and controlled data in chess - a test of complex cognitive function. It's likely that other stimulants could do the same so this does raise interesting issues for regulators of these activities. Clearly more research is needed"

European College of Neuropsychopharmacology

Related Caffeine Articles:

Systematic review confirms longstanding caffeine intake recommendations
A rigorous, new scientific Systematic Review paper on caffeine safety confirms the results of the widely-cited Health Canada literature review (2003), which concluded that adverse health effects were not associated with caffeine intake levels at ≤400 mg/day for adults (which is the equivalent of about 4 cups of coffee/day, and 90 percent of Americans typically consume less than this amount ), ≤300 mg/day for pregnant women and ≤2.5 mg/kg-day for children and adolescents.
Caffeine boosts enzyme that could protect against dementia, finds IU study
A study by Indiana University researchers has identified 24 compounds -- including caffeine -- with the potential to boost an enzyme in the brain shown to protect against dementia.
For women, caffeine could be ally in warding off dementia
Higher caffeine intake in women is associated with reduced odds of developing dementia or cognitive impairment, according to the results of a new study published in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences.
For women, caffeine could be ally in warding off dementia
Higher caffeine intake in women is associated with reduced odds of developing dementia or cognitive impairment, according to the results of a new study published in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences.
Light and caffeine improve driver alertness: CARRS-Q study
Bright light combined with caffeine can improve driving performance and alertness of chronically sleep deprived young drivers, according to a Queensland University of Technology road safety study.
Caffeine has little to no benefit after 3 nights of sleep restriction
A new study found that after restricting sleep to 5 hours per night, caffeine use no longer improved alertness or performance after three nights.
Increased education could help adolescents limit caffeine consumption
Caffeine is the most available and widely used psychoactive substance in the world and is the only drug legally accessible and socially acceptable for consumption by children and adolescents.
Moderate amounts of caffeine during pregnancy do not harm baby's IQ
Women drinking and eating moderate amounts of caffeine during pregnancy should be reassured that they are not harming their child's intelligence, according to a study from The Research Institute at Nationwide Children's Hospital that was published in the American Journal of Epidemiology.
Brief cognitive-behavioral therapy helps those with problematic caffeine use
Engaging in brief, cognitive-behavioral therapy is an effective treatment for helping people with problematic caffeine use lower their caffeine consumption, according to a new study coauthored by Laura M.
How to stay awake without caffeine
You're tired and you need an energy boost, but you don't want the jitters from caffeine.

Related Caffeine Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...